Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | PRCP | P42785 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7381926 | 0.99 | MEN1 (1.00) | SIGMAR1MEN1KMT2AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7384604 | 0.98 | MEN1 (0.98) | SIGMAR1MEN1KMT2AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7385268 | 0.93 | MEN1 (0.88) | SIGMAR1MEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL9637705 | 0.90 | MAPK1 (0.97) | SIGMAR1MEN1KMT2AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7377040 | 0.89 | MAPK1 (1.00) | SIGMAR1MEN1KMT2AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7378086 | 0.89 | MAPK1 (1.00) | SIGMAR1MEN1KMT2AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7377177 | 0.89 | MAPK1 (1.00) | SIGMAR1MEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL11120309 | 0.88 | SIGMAR1 (0.79) | SIGMAR1MEN1KMT2AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL8097430 | 0.85 | MEN1 (0.95) | SIGMAR1MEN1KMT2AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7380625 | 0.83 | MEN1 (0.92) | SIGMAR1MEN1KMT2AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090434-A1 | METHODS OF TREATING AND/OR PREVENTING POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| EP-4561566-A1 | COMPOSITIONS AND METHODS FOR PREVENTION OF COGNITIVE DECLINE CAUSED BY DEGENERATIVE DISEASES | Anavex Life Sciences Corp. (US) | 2025-06-04 | — | — | EP | claimed |
| EP-4562184-A2 | THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | Anavex Life Sciences Corp. (US) | 2025-06-04 | — | — | EP | claimed |
| CN-119997948-A | Compositions and methods for preventing cognitive decline caused by degenerative diseases | 阿纳韦克斯生命科学公司 | 2025-05-13 | — | — | CN | claimed |
| US-20240417798-A1 | THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | ANAVEX LIFE SCIENCES CORP. | 2024-12-19 | — | — | US | claimed |
| EP-4436573-A1 | THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | Anavex Life Sciences Corp. (US) | 2024-10-02 | — | — | EP | claimed |
| US-20240299317-A1 | Fenfluramine for Treatment of Conditions Associated with Spreading Depolarization | ZOGENIX INTERNATIONAL LIMITED (GB) | 2024-09-12 | — | — | US | claimed |
| CN-118613282-A | Treatment options and treatments for neurodegenerative disorders | 阿纳韦克斯生命科学公司 | 2024-09-06 | — | — | CN | claimed |
| WO-2024111636-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | 国立大学法人千葉大学 | 2024-05-30 | — | — | WO | claimed |
| WO-2021234324-A1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | REST THERAPEUTICS (FR) | 2021-11-25 | — | — | WO | claimed |
| EP-3880209-A1 | COMPOSITIONS AND METHODS FOR REGULATING INFLAMMATION | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3104847-B1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) | 2020-11-11 | — | — | EP | claimed |
| WO-2020118086-A1 | COMPOSITIONS AND METHODS FOR REGULATING INFLAMMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-06-11 | — | — | WO | claimed |
| EP-3104847-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | Mta Támogatott Kutatócsoportok Irodája (HU) | 2016-12-21 | — | — | EP | claimed |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2016-12-01 | — | — | US | claimed |
| WO-2015118365-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2015-08-13 | — | — | WO | claimed |
| EP-0495084-A1 | ARYLCYCLOALKANEPOLYALKYLAMINES | SRI INTERNATIONAL (US) | 1992-07-22 | — | — | EP | claimed |
| WO-1992002481-A1 | ARYLCYCLOALKANEPOLYALKYLAMINES | SRI INTERNATIONAL (US) | 1992-02-20 | — | — | WO | claimed |
| US-5086054-A | Selective high-affinity ligands to sigma boding sites, administering, amipsychotic, antiarrhythmia, antiischemic agents anticonvulsants, reduced side effects | SRI INTERNATIONAL (US) | 1992-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299317-A1 | Fenfluramine for Treatment of Conditions Associated with Spreading Depolarization | SIGMAR1, HTR1A, HTR1E | SIGMAR1 1/4885MEN1 2734/4885KMT2A 3931/4885 |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885MEN1 4822/4885KMT2A 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.